Should You Buy Medtronic Stock as Its Hugo Surgical Robot Gains Ground?

Medtronic's stock is down 3% this year despite strong fundamentals, presenting a buying opportunity for growth-oriented investors. The company's Hugo robotic-assisted surgery system is gaining traction and eroding competitor Intuitive Surgical's market dominance. With Q1 FY2027 revenue up 13.7% YoY, raised full-year guidance, a near-Dividend King status (49 consecutive years of dividend increases), and attractive valuation metrics, analysts view the stock as undervalued compared to peers.